icaritin and Lupus-Erythematosus--Systemic

Systemic lupus erythematosus (SLE) is a female predominant autoimmune disease characterized by multi-organ dysfunctions. However, current available therapies control the disease at the cost of many potential adverse effects. The development of safer and more effective therapies for SLE is a critical unmet need. Icaritin (ICT) is an active monomer extracted from Chinese herbals named the Epimedium genus. In this study, we found that ICT exhibited the capacity of regulating Foxp3/IL17a balance, enhancing Treg cell suppressive activities, and inhibiting over-activation of CD4(+)T cells from SLE. We also observed that ICT regulated Foxp3/IL17a balance by increasing STAT5b expression and histone methylation modification. Subsequent experiments further confirmed that ICT-treated mice exhibited amelioration of renal damages and suggested that ICT may be a potential new drug for the treatment of SLE.

Topics: Animals; Blotting, Western; Enzyme-Linked Immunosorbent Assay; Female; Flavonoids; Flow Cytometry; Fluorescent Antibody Technique; Forkhead Transcription Factors; Gene Expression Regulation; Humans; Interleukin-17; Lupus Erythematosus, Systemic; Mice; Mice, Inbred MRL lpr; Real-Time Polymerase Chain Reaction